Stryker (NYSE:SYK) Director Sells $17,005,000.00 in Stock

Posted by George Bondi on Aug 23rd, 2026

Stryker Corporation (NYSE:SYK – Get Free Report) Director Ronda Stryker sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Stryker Stock Up 0.7%

Shares of NYSE:SYK opened at $329.86 on Friday. The company has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a 50 day moving average of $326.99 and a two-hundred day moving average of $332.64. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Institutional Investors Weigh In On Stryker

Hedge funds and other institutional investors have recently modified their holdings of the stock. Norges Bank bought a new position in shares of Stryker during the fourth quarter worth about $1,822,272,000. Bank of America Corp DE bought a new stake in Stryker in the second quarter valued at about $1,404,284,000. Auto Owners Insurance Co increased its holdings in Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the last quarter. Legal & General Group Plc acquired a new stake in Stryker during the second quarter valued at approximately $707,212,000. Finally, Jupiter Topco LLC acquired a new stake in Stryker during the second quarter valued at approximately $681,581,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of several recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. Finally, Wells Fargo & Company dropped their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Get Our Latest Stock Analysis on Stryker

Stryker Company Profile

(Get Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.